Ok Lets run some numbers onthe DSMB look at the CD-12
They did the Look at 149 patients inrolled
Someone else on this board pointed out that we could only have about 100-120 Patients that completed the 28 days of the trial.
So lets take the middle ground 110 patients.
36 - Placebo
74 - Leronlimab
25% Mortality rate of people in the ICU for covid
110 X .25 = 27.5 Possible deaths
8.75 Placebo Deaths
18.5 Leronlimab group
If there is 64% fewer SAEs in the leronlimab group M2M then the same here might be,
18.5 X .36 = 6.66 patients die in the leronlimab gruop

A few of questions:
If the numbers were this good would they stop the trial? (I don't know how to calculate P-Values)
If there were fewer deaths in the Placebo group 4-6 How does that skew the numbers?
Are all these patients in the ICU or just the Critical patients? If so the deaths would be alot lower
At what patient count do we get better statistical significance? At the 195 Readout we may only have 140-160 that hve completed the trial.